Effect of Anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence - Journal of the American Medical Association - 2016

Brief Summary:

In a small open label trial, patients with colchicine resistant, steroid dependent recurrent pericarditis, the IL-1B antagonist anakinra was associated with a dramatic reduction in the pericarditis recurrence rate. At 14 months, only 2 out of 11 patients on anakinra experienced recurrent pericarditis (18%) compared to 9 out of 10 (90%) in the placebo group.